Inverted head and shoulders. Buyers absorbing potential dilution quickly. Too much riding on the trial launch and WORLD WIDE exposure. Not saying it'll happen, but I like the potential to be back in the .20's and with trial launch, with impressive protocols, we could see quite a run up. Whoever took the deal is looking for IPIX's success, not just trying to make a buck and dilute the crap out of us. Otherwise we'd have been punching .10 or lower already.

But that, my friends, is ONLY my opinion.